Cart 0
TRAIL, Fas Ligand, TNF and TLR3 in Cancer
Click to zoom

Share this book

TRAIL, Fas Ligand, TNF and TLR3 in Cancer

Softcover reprint of the original 1st ed. 2017

Book Details

Format Paperback / Softback
ISBN-10 3319860062
ISBN-13 9783319860060
Edition Softcover reprint of the original 1st ed. 2017
Publisher Springer International Publishing AG
Imprint Springer International Publishing AG
Country of Manufacture GB
Country of Publication GB
Publication Date Aug 12th, 2018
Print length 317 Pages
Product Classification: Oncology
Ksh 23,400.00
Werezi Extended Catalogue 0 in stock

Delivery Location

Delivery fee: Select location

Secure
Quality
Fast
Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy.

This volume provides the current understanding of death receptor''s/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.


Get TRAIL, Fas Ligand, TNF and TLR3 in Cancer by at the best price and quality guaranteed only at Werezi Africa's largest book ecommerce store. The book was published by Springer International Publishing AG and it has pages.

Mind, Body, & Spirit

Shopping Cart

Africa largest book store

Sub Total:
Ebooks

Digital Library
Coming Soon

Our digital collection is currently being curated to ensure the best possible reading experience on Werezi. We'll be launching our Ebooks platform shortly.